BB
PTCT icon

BB Biotech’s PTC Therapeutics PTCT Stock Holding History

BB Biotech’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-682,912
Closed -$6.72M – 30
2017
Q1 		$6.72M Hold
682,912
– – 0.22% 29
2016
Q4 		$7.45M Sell
682,912
-500,000
-42% -$5.25M 0.28% 27
2016
Q3 		$16.6M Hold
1,182,912
– – 0.58% 25
2016
Q2 		$8.3M Hold
1,182,912
– – 0.33% 28
2016
Q1 		$7.62M Sell
1,182,912
-120,000
-9% -$2.08M 0.3% 29
2015
Q4 		$42.2M Hold
1,302,912
– – 1.19% 20
2015
Q3 		$34.8M Buy
1,302,912
+50,000
+4% +$2.14M 1.1% 23
2015
Q2 		$60.3M Buy
1,252,912
+75,000
+6% +$4.38M 1.63% 20
2015
Q1 		$71.7M Sell
1,177,912
-50,000
-4% -$3.05M 2.14% 17
2014
Q4 		$63.6M Buy
+1,227,912
New +$54.1M 2.06% 18

Other funds holding PTCT

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech's PTCT Position: Q2 2017 in Review

BB Biotech sold out of PTC Therapeutics (PTCT) in Q2 2017, closing a stake of 682,912 shares — an estimated $6.72M sold.

BB Biotech first reported a position in PTCT in Q4 2014 and held it in 10 quarters. The position peaked at $71.7M in Q1 2015. 114 funds tracked by Wall St. Rank hold PTCT as of Q2 2017.

  • BB Biotech reported no remaining PTC Therapeutics position as of Q2 2017 after selling out during the quarter.
  • BB Biotech sold 682,912 PTC Therapeutics shares in Q2 2017, an estimated $6.72M.
  • BB Biotech first reported a position in PTC Therapeutics in Q4 2014 and held it in 10 quarters.
  • BB Biotech's PTC Therapeutics position peaked at $71.7M in Q1 2015.
  • 114 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2017.

Based on BB Biotech's 13F filing for Q2 2017, filed 11 Aug 2017.